VERTEX PHARMACEUTICALS INC / MA
VRTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VRTX
Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, with approved therapies in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, and a late-stage pipeline including povetacicept for IgA nephropathy.
Key risk: Drug development failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$137.21B
Cash Runway
—
Lead Asset
alyftrek (Approved)Next Catalyst
Phase3_Topline · Oct 30, 2026Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 65 clinical trials · 24 catalysts · 9 FDA decisions for VERTEX PHARMACEUTICALS INC / MA.
Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, with approved therapies in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, and a late-stage pipeline including povetacicept for IgA nephropathy.
- Vertex has seven approved medicines: five for cystic fibrosis, one for severe sickle cell disease and transfusion-dependent beta thalassemia, and one for moderate-to-severe acute pain [sec_mda · as of 2026-08-04].
- Total revenues for 2025 were $12 billion, representing 9% growth versus 2024, with a strong balance sheet ending the year with $12.3 billion in cash and investments [sec · filed 2026-04-02].
- As of 2026-06-30, the company reported cash & equivalents of $6,154.1M, total revenue of $3,333.9M, net income of $1,099.8M, and shareholders' equity of $16,409.6M [latest reported financials].
- The company is preparing for the anticipated launch of povetacicept for IgA nephropathy and has multiple late-stage programs in pivotal development [sec · filed 2026-04-02] [sec_mda · as of 2026-08-04].
- Vertex invests in multiple modalities including small molecules, biologics, cell therapies, and genetic therapies, and uses biomarkers to advance candidates into clinical trials [sec · filed 2025-04-03].
What works
- Vertex has a strong financial position with $12.3 billion in cash and investments as of year-end 2025 and a growing revenue base of $12 billion in 2025 [sec · filed 2026-04-02].
- The company has a diversified pipeline spanning multiple disease areas (CF, SCD, TDT, acute pain, IgAN, type 1 diabetes) and modalities, reducing reliance on any single program [sec_mda · as of 2026-08-04].
- Vertex has a track record of bringing transformative medicines to market, with seven approved drugs and a near-term launch opportunity for povetacicept in IgAN [sec_mda · as of 2026-08-04].
What to weigh
- Drug development is inherently risky: most potential products never progress into development, and most that do never receive marketing approval [sec_mda · as of 2026-08-04].
- The company's revenue is heavily concentrated in CF medicines, with CF products accounting for the majority of product revenues in the first quarter of 2026 [sec_mda · as of 2026-05-05].
- Vertex faces competition and rapid changes in focus as new data and scientific insights emerge, which can lead to program discontinuations [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Vertex's 2025 total revenues were $12 billion, with 9% growth over 2024.
“our strong performance in 2025 resulted in total revenues of $12 billion , representing 9% growth versus 2024”
SEC filings · April 2, 2026
Vertex is preparing for the launch of povetacicept for IgAN.
“We are also preparing for the anticipated launch of povetacicept, a potential treatment for IgA nephropathy ("IgAN").”
SEC MD&A · August 4, 2026
Vertex uses multiple modalities and biomarkers to advance candidates.
“Our research and development approach also includes pursuing multiple modalities tailored to the specific disease area target under investigation, using biomarkers that translate from the bench to the bedside”
SEC filings · April 3, 2025
Catalyst timeline
- 2026-10-30 · Phase3_Topline — Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina — Topline data from a long-term safety and efficacy study of the CF triple combination will inform potential label expansion.
- 2027-01-25 · Phase3_Topline — Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subj — Topline data from a long-term safety study of suzetrigine in acute pain will support the drug's profile.
- 2027-04-06 · Phase3_Topline · suzetrigine — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrig — Placebo-controlled efficacy and safety data for suzetrigine in acute pain will be a key readout for the program.
- 2027-04-06 · Phase3_Topline — Phase 3 Topline: A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Iv — Long-term safety and efficacy data for the CF triple combination will support ongoing use.
- 2027-05-31 · Phase3_Topline · suzetrigine — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety — Active-controlled data for suzetrigine will compare it to standard of care in acute pain.
- 2027-06-06 · Phase3_Topline — Phase 3 Topline: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects — Pediatric data for the CRISPR-based therapy CTX001 in SCD/beta thalassemia will be a major milestone.
- 2027-06-09 · Phase3_Topline — Phase 3 Topline: A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified — Additional efficacy and safety data for CTX001 in a broader population.
- 2027-09-17 · Phase3_Topline — Phase 3 Topline: A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 — Phase 3 data for VX-880, a cell therapy for type 1 diabetes, will be a key pipeline catalyst.
Risks & what to watch (3)›
Key risks
- Drug development failure risk — Most potential drug products never progress into development, and most that do never receive approval [sec_mda · as of 2026-08-04].
- Revenue concentration in CF — CF medicines generated the majority of product revenues in Q1 2026, creating dependence on a single therapeutic area [sec_mda · as of 2026-05-05].
- Rapid pipeline reprioritization — Vertex frequently evaluates programs and may change focus based on new data, leading to discontinuations [sec_mda · as of 2026-08-04].
What to watch
- Phase 3 topline results for VX-121/TEZ/D-IVA in CF expected on 2026-10-30 [upcoming catalysts].
- Phase 3 topline results for suzetrigine in acute pain expected on 2027-01-25 and 2027-04-06 [upcoming catalysts].
- Phase 3 topline results for CTX001 in pediatric SCD/beta thalassemia expected on 2027-06-06 [upcoming catalysts].
- Phase 3 topline results for VX-880 in type 1 diabetes expected on 2027-09-17 [upcoming catalysts].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run VERTEX PHARMACEUTICALS INC / MA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VERTEX PHARMACEUTICALS INC / MA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.35 · 1% dilution
Lead: Approved
8 candidates
24 upcoming, next in ~61d
0 buys · 19 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,682
Total value held
$81.91B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,025,620 | $14.75B |
| blackrock, inc. | 23,969,517 | $10.70B |
| state street corp | 11,730,139 | $5.24B |
| geode capital management, llc | 6,139,621 | $2.73B |
| vanguard portfolio management llc | 5,145,609 | $2.30B |
| janus henderson group plc | 4,263,054 | $1.90B |
| alliancebernstein l.p. | 3,910,786 | $1.77B |
| wellington management group llp | 3,212,589 | $1.43B |
| morgan stanley | 3,188,881 | $1.42B |
| ubs am, a distinct business unit of ubs asset management americas llc | 3,057,396 | $1.37B |
Showing top 10 of 1,682 institutional holders of VERTEX PHARMACEUTICALS INC / MA. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.9%
- Days to cover
- 3.7
- Shares short
- 4,172,829
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for VERTEX PHARMACEUTICALS INC / MA?
Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, with approved therapies in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, and a late-stage pipeline including povetacicept for IgA nephropathy.
What is VERTEX PHARMACEUTICALS INC / MA's lead drug candidate?
VERTEX PHARMACEUTICALS INC / MA's most advanced tracked candidate is alyftrek (Approved).
What is VERTEX PHARMACEUTICALS INC / MA's next catalyst?
VERTEX PHARMACEUTICALS INC / MA's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina" — expected October 30, 2026.
Who is the CEO of VERTEX PHARMACEUTICALS INC / MA?
Dr. Reshma Kewalramani FASN, M.D. is the chief executive officer of VERTEX PHARMACEUTICALS INC / MA (VRTX).
Where is VERTEX PHARMACEUTICALS INC / MA headquartered?
VERTEX PHARMACEUTICALS INC / MA (VRTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.